Literature DB >> 24049426

Linaclotide pharmacodynamics.

Robert W Busby1, George Zhang.   

Abstract

Entities:  

Year:  2013        PMID： 24049426      PMCID： PMC3776486     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  3 in total

1.  Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.

Authors:  Robert W Busby; Alexander P Bryant; Wilmin P Bartolini; Etchell A Cordero; Gerhard Hannig; Marco M Kessler; Shalina Mahajan-Miklos; Christine M Pierce; Robert M Solinga; Li Jing Sun; Jenny V Tobin; Caroline B Kurtz; Mark G Currie
Journal:  Eur J Pharmacol       Date:  2010-09-20       Impact factor: 4.432

2.  Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.

Authors:  Robert W Busby; Marco M Kessler; Wilmin P Bartolini; Alexander P Bryant; Gerhard Hannig; Carolyn S Higgins; Robert M Solinga; Jenny V Tobin; James D Wakefield; Caroline B Kurtz; Mark G Currie
Journal:  J Pharmacol Exp Ther       Date:  2012-10-22       Impact factor: 4.030

3.  Linaclotide (Linzess) for Irritable Bowel syndrome With Constipation and For Chronic Idiopathic Constipation.

Authors:  Rachel Hutchins Thomas; Kyle Allmond
Journal:  P T       Date:  2013-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.